Clinical Trials Directory

Trials / Completed

CompletedNCT02596100

A Bioequivalence Study to Compare the Pharmacokinetics of Two Betrixaban Formulations

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
52 (actual)
Sponsor
Portola Pharmaceuticals · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

This is a single center open label randomized 4-period 2-sequence replicated crossover design study. A total of 52 healthy subjects will be randomized.

Detailed description

Serial blood samples will be obtained for PK evaluation.

Conditions

Interventions

TypeNameDescription
DRUGBetrixaban

Timeline

Start date
2015-09-01
Primary completion
2015-11-01
Completion
2015-11-01
First posted
2015-11-04
Last updated
2023-08-08

Source: ClinicalTrials.gov record NCT02596100. Inclusion in this directory is not an endorsement.